Resultats de la cerca - V.R. Peddi

  • Mostrar 1 - 6 resultats de 6
Refinar resultats
  1. 1
    Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus

    Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus per Fuad S. Shihab, Y. Qazi, S. Mulgaonkar, Kevin McCague, Dharmesh Patel, V.R. Peddi, David R. Shaffer

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety

    Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety per Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Graeme R. Russ, Brad A. Marder, C. Hahn, H. Li, Alison Flynn, Sam Schulman

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft.

    Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft. per Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Frutuoso, Brad A. Marder, Graeme R. Russ, Alison Flynn, C. Hahn, Michael A. Tortorici, Sam Schulman

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data

    Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data per Yasir Qazi, David R. Shaffer, Bruce Kaplan, D.Y. Kim, Fu L. Luan, V.R. Peddi, Fuad S. Shihab, Stephen J. Tomlanovich, S. Yilmaz, Kevin McCague, Dharmesh Patel, S. Mulgaonkar

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters.

    Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters. per Fritz Diekmann, Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Brad A. Marder, G. R. Russ, Alison Flynn, C. Hahn, H. Li, Michael A. Tortorici, Sam Schulman

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients

    Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients per Stéphan Busque, Joseph R. Leventhal, Daniel C. Brennan, Steven Steinberg, Göran B. Klintmalm, T. Shah, S. Mulgaonkar, Jonathan S. Bromberg, F. Vincenti, Sundaram Hariharan, Douglas P. Slakey, V.R. Peddi, Rosemary A. Fisher, Nervin Lawendy, C. Wang, Gordon Chun‐Kau Chan

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: